Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NRF-2013M3C7A1072998 | Other Grant/Funding Number | NRF-2013M3C7A1072998 | |
| NRF-2013M3C7A1069644 | Other Grant/Funding Number | NRF-2013M3C7A1069644 | |
| NRF-2014M3C7A1046042 | Other Grant/Funding Number | NRF-2014M3C7A1046042 | |
| NRF-2014M3C7A1046037 | Other Grant/Funding Number | NRF-2014M3C7A1046037 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry of Science and ICT, Republic of Korea | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective cohort study for cognitively normal (young and old), mild cognitive impairment, and Alzheimer's disease people
The aim of the study is 1) to search new biomarkers and develop clinically applicable early diagnosis and prediction methods of Alzheimer's disease, and 2) to investigate how the proposed lifetime risk and protective factors for Alzheimer's disease contribute to pathological hallmarks of AD or other brain changes in living human through annual comprehensive clinical and neuropsychological evaluation and biannual brain imaging (MRI and MRA, Fluorodeoxyglucose(FDG)-PET, Pittsburgh compound B (PiB)-PET), AV--1451 PET, and body specimen (blood, gene, and hair) analysis.
* Note: AV-1451 PET will not be applied to whole subjects, but to 210 subjects (30 young CN, 60 old CN, 60 MCI, and 60 AD).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Young normal controls |
| ||
| Elderly normal controls |
| ||
| MCI (Mild cognitive impairment) |
| ||
| AD (Alzheimer's diseases) |
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The amount of brain amyloid deposition | Group difference in baseline brain amyloid deposition (on PIB PET) and the relationship between the amount of brain amyloid deposition and clinical, neuropsychological, neuroimaging, genetic, biochemical measurement will be investigated. | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Group difference for each clinical, neuropsychological, structural and functional neuroimaging, tau imaging, genetic, biochemical measures | Group difference for clinical, neuropsychological, structural and functional neuroimaging, tau imaging, genetic, biochemical variables and correlations among these variables will be investigated. | baseline |
Not provided
Participants will be classified as either Alzheimer's disease(AD) group, mild cognitive impairment(MCI) group, elderly normal controls or young normal controls. Specific inclusion criteria for each group is described below.
[Inclusion criteria: AD]
[Inclusion criteria: MCI (amnestic)]
[Inclusion criteria: Elderly normal controls]
[Inclusion criteria: Young normal controls]
[Exclusion criteria: general]
Not provided
Not provided
Young and elderly normal controls: community-based population AD and MCI: clinic or community-based population
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dong Young Lee, MD, PhD | Department of Psychiatry, Seoul National University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Seoul | 110-744 | South Korea |
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D060825 | Cognitive Dysfunction |
| D004194 | Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma, Serum, DNA, RNA, hair, and stool
| Change of brain amyloid deposition | The change of brain amyloid deposition and its relation to the clinical, neuropsychological, neuroimaging, genetic and biochemical variables will be assessed. | baseline, 2yr, 4yr |
| Change of clinical, neuropsychological measures | The change of clinical, neuropsychological measurement and the relationship between these variables and other biomarkers will be assessed. | baseline, 1yr, 2yr,3yr, 4yr |
| Change of structural and functional neuroimaging measures | The change of structural and functional MRI measures and glucose metabolism of the brain the relationship between these variables and other clinical, neuropsychological, neuroimaging, biochemical, genetic biomarkers will be assessed. | baseline, 2yr, 4yr |
| Change of biochemical measures | The change of blood or hair-based biochemical measures and the relationship between these variables and other clinical, neuropsychological, neuroimaging, biochemical, genetic biomarkers will be assessed. | baseline, 2yr, 4yr |
| Chage of tau imaging measures | The change of tau PET imaging measures and the relationship between these measures and other clinical, neuropsychological, neuroimaging, biochemical, genetic biomarkers will be assessed. | 2yr, 4yr |
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D003072 | Cognition Disorders |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |